Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Ligand Pharmaceuticals Inc

NASDAQ: LGND · Life Sciences · 11 alerts · CIK 886163

Share price
$301.71Close, Nov 16
Market cap
$6.04B
Shares outstanding
20MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Ligand Pharmaceuticals Inc filings on SEC EDGAR ↗

4:47 PM ET 10-Q
Financial Results

Ligand Pharmaceuticals Q3 2026 Results: Net Loss of $28.5M

For the nine months ended September 30, 2026, Ligand Pharmaceuticals reported total revenues and income of $194.2 million and net income of $6.7 million, a decrease from $79.7 million in the prior year period. The company significantly expanded its balance sheet through the acquisition of XOMA, resulting in total assets increasing to $2.24 billion compared to $1.56 billion at year-end 2025.

Key figure
Net loss $28.5M
7:15 AM ET 8-K
Financial Results

Ligand Pharmaceuticals Financial Results

Ligand Pharmaceuticals reported Q3 2026 financial results, highlighted by a 51% year-over-year increase in royalty revenue to $70.3 million, driven by the XOMA portfolio and commercial momentum of Filspari. The company raised its full-year 2026 adjusted diluted EPS guidance to a range of $9.50 to $9.75 while reaffirming its total revenue guidance.

Term
Q3 2026

“Ligand delivered another strong quarter, with royalty revenue growing 51% year-over-year, driven by contribution from the XOMA portfolio and continued commercial momentum across our key royalty assets, including Filspari.”

Todd Davis, CEO of Ligand

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.